Therapeutic plasma exchange in gastric signet ring cell carcinoma presenting as microangiopathic hemolytic anemia: A rare case report.
gastric carcinoma
microangiopathic hemolytic anemia
signet ring cell carcinoma
therapeutic plasma exchange
thrombotic microangiopathy
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
12
08
2022
received:
02
06
2022
accepted:
29
08
2022
pubmed:
21
9
2022
medline:
3
12
2022
entrez:
20
9
2022
Statut:
ppublish
Résumé
Microangiopathic hemolytic anemia (MAHA) defines a group of disorders characterized by the formation of microthrombi in capillaries and arterioles and the fragmentation of erythrocytes that pass through. Cancer-related MAHA is a rare but serious condition that is encountered in patients diagnosed with a malignancy. This clinical picture is thought to be linked to certain tumor characteristics; particularly, adenocarcinoma histology, vascular invasion, and bone marrow infiltration. MAHA is most commonly associated with tumors of gastric, prostate, and breast origin. The optimal treatment is not clear; however, there is evidence for the importance of promptly starting an effective antineoplastic regimen and it was also reported that administering therapeutic plasma exchange (TPE) therapy for immunocomplex removal could be beneficial for patients with symptoms of bleeding and thrombosis. Here, we present a case that presented a picture of MAHA secondary to gastric signet-ring cell adenocarcinoma (SRCC). The clinical picture was initially evaluated as thrombotic thrombocytopenic purpura and the patient benefited significantly from the TPE treatment administered before the adenocarcinoma diagnosis was confirmed. In this period, epistaxis stopped, platelet count increased from 25 × 10
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
606-610Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Shenkman B, Einav Y. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification. Autoimmun Rev. 2014;13(4-5):584-586. doi:10.1016/j.autrev.2014.01.004
Zini G, d'Onofrio G, Briggs C, et al. International Council for Standardization in Haematology (ICSH). ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol. 2012;34(2):107-116. doi:10.1111/j.1751-553X.2011.01380.x
Demircioğlu S, Ekinci Ö, Doğan A, Demir C. Relapsed/refractory thrombotic thrombocytopenic purpura treated with N-acetylcysteine: a case report. Scott Med J. 2018 Nov;63(4):122-124. doi:10.1177/0036933018775240
Ekinci O, Candar O, Dogan A, Esen R, Demir C. Disseminated intravascular coagulation: a single center experience. East J Med. 2018;23(1):31-35. doi:10.5505/ejm.2018.48568
Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 Feb;15(2):312-322. doi:10.1111/jth.13571
Abdel Samie A, Sandritter B, Theilmann L. Severe microangiopathic hemolytic anemia as first manifestation of a CUP syndrome. Rapid hematologic remission under polychemotherapy. Med Klin (Munich). 2004;99:148-153.
Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012 Jul;91(4):195-205. doi:10.1097/MD.0b013e3182603598 PMID: 22732949.
Genereau T, De Cagny B, Branger B, et al. EMicroangiopathic hemolytic anemia associated with cancers. Symptomatic treatment by plasma exchange. Ann Med Interne (Paris). 1994;145:365Y368.
Morton JM, George JN. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J Oncol Pract. 2016 Jun;12(6):523-530. doi:10.1200/JOP.2016.012096
Arkenau HT, Müssig O, Buhr T, Jend HH, Porschen R. Microangiopathic hemolytic anemia (MAHA) as paraneoplastic syndrome in metastasized signet ring cell carcinomas: case reports and review of the literature. Z Gastroenterol. 2005;43:719-722.
Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol. 1987;24:161-177.
Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol. 2010 Jul;85(1):43-50. doi:10.1111/j.1600-0609.2010.01448.x
Dally N, Kashlikov M, Farah R. Microangiopathic hemolytic anemia as presenting symptom of gastric adenocarcinoma. Harefuah. 2016;155(4):212-255. Hebrew.
Shin SY, Park H, Chae SW, Woo HY. Microangiopathic hemolytic anemia as the first manifestation of metastatic signet ring cell carcinoma of unknown origin: a case report and review of the literature. Korean J Lab Med. 2011 Jul;31(3):157-161. doi:10.3343/kjlm.2011.31.3.157
Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016 Jun;28(10):649. doi:10.3332/ecancer.2016.649